CDER - Office of New Drugs - Organization - Text version
The following header reflects the organizational hierarchy.
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF NEW DRUGS
The following is the communication box containing information to assist anyone who may want to communicate with the depicted organization via telephone, facsimile or mail.
WO Bldg 22 Rm: 6304
10903 New Hampshire Ave.
Silver Spring, MD 20993
The following is the Food and Drug Administration’s, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of New Drugs organization structure depicting all the organizational structures reporting to the Office Director. These organizational structures are organized in sequential order by their assigned Standard Administrative code (Alphanumeric sequence of characters beginning with the letter D).
Each organizational component will be depicted in the following standard format:
Title of organization.
Position title of the manager.
Military rank if any, first name, middle initial if any, last name, post graduate degrees if any, and if the individual is designated as acting.
Standard Administrative code.
John K. Jenkins, M.D.
Reports directly to the Office Director:
RADM Sandra L. Kweder, M.D.
OFFICE OF DRUG EVALUATION I
Ellis Unger, M.D.
Robert Temple, M.D. (Acting)
OFFICE OF DRUG EVALUATION II
Curtis Rosebraugh, M.D.
OFFICE OF DRUG EVALUATION III
Julie G. Beitz, M.D.
Victoria Kusiak, M.D.
OFFICE OF DRUG EVALUATION IV
Charles J. Ganley, M.D.
Shaw T. Chen, M.D.
OFFICE OF ANTIMICROBIAL PRODUCTS
Edward M. Cox, M.D., M.P.H.
John Farley, M.D., M.P.H.
OFFICE OF HEMATOLOGY AND ONCOLOGY PRODUCTS
Richard Pazdur, M.D.
Approved by the FDA Reorganization Coordinator and Principal Delegations Control Officer